Advertisement
ABBV or IONS or PRAX
Which Stock Would AI Choose? AbbVie (ABBV) vs. Ionis Pharmaceuticals (IONS) vs. Praxis Precision Medicines (PRAX) Stock Comparison
Key Takeaways
- ABBV offers stability with a 3.15% dividend yield and low beta of 0.33, showing modest YTD gains of 2.27% amid post-Humira transition success via Skyrizi and Rinvoq.
- IONS demonstrates strong momentum with 116% 1-year returns, fueled by TRYNGOLZA sales growth and FDA priority review for olezarsen in hypertriglyceridemia.
- PRAX leads in explosive growth at 689% over 1 year and YTD 2.45%, driven by NDA preparations for ulixacaltamide in essential tremor and high analyst targets averaging $601.
- ABBV provides diversified revenue and reliable income, contrasting IONS and PRAX's biotech volatility with betas of 0.36 and 3.01.
- Recent relative performance favors PRAX for growth traders, while ABBV suits conservative investors seeking market positioning in immunology and oncology.
- All three exhibit positive analyst sentiment, with average price targets implying upside: ABBV $249, IONS $94, PRAX $601.
Introduction
This stock comparison examines ABBV, a biopharmaceutical giant; IONS, a commercial-stage RNA-targeted biotech; and PRAX, a clinical-stage CNS precision medicines firm. These stocks represent varying stages of maturity in the healthcare sector, from established revenue generators to high-growth pipeline developers. Traders seeking relative performance insights and investors eyeing sector exposure amid recent market volatility will find value in analyzing their business models, recent momentum, and valuation sensitivities. With biotech catalysts like FDA reviews and NDA filings influencing sentiment, this overview highlights key contrasts in stability, growth potential, and risk profiles.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a research-based biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with key products including Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox, and Vraylar. In recent market activity, ABBV has traded around $222, reflecting modest YTD gains of 2.27% and 8% over one year, underperforming the S&P 500's broader returns. Sentiment remains supported by successful post-Humira transitions, strong pipeline advancements in oncology and immunology, and a robust dividend history yielding 3.15%. Recent weeks have seen dips aligned with market pullbacks, influenced by competition in immunology, yet analyst targets averaging $249 signal confidence in growth levers like new therapies and acquisitions.
IONS Overview and Recent Performance
Ionis Pharmaceuticals, Inc. (IONS) specializes in RNA-targeted medicines for rare diseases, with marketed products like TRYNGOLZA for familial chylomicronemia syndrome, DAWNZERA for hereditary angioedema, WAINUA for ATTRv-PN, and SPINRAZA for spinal muscular atrophy. Trading near $71, IONS has posted YTD gains of 10% and explosive 116% 1-year returns, driven by TRYNGOLZA's $108 million 2025 sales and FDA priority review for olezarsen in severe hypertriglyceridemia. Recent performance reflects positive Phase 3 data and raised peak sales expectations over $2 billion for FCS/sHTG opportunities. Sentiment shifts positively on commercial momentum and pipeline progress, though volatility persists with no dividend and a beta of 0.36; analysts target $94 on average.
PRAX Overview and Recent Performance
Praxis Precision Medicines, Inc. (PRAX) develops therapies for CNS disorders via neuronal excitation-inhibition imbalance, leveraging Cerebrum small molecules and Solidus antisense platforms. Lead candidates include ulixacaltamide (NDA for essential tremor), relutrigine (NDA for SCN2A/8A-DEEs), vormatrigine (Phase 3 epilepsy), and elsunersen (Phase 3 SCN2A-DEE). At around $302, PRAX boasts YTD 2.45% and staggering 689% 1-year gains, propelled by positive Essential3 Phase 3 data, Breakthrough Therapy designations, and NDA submissions expected mid-February 2026. High beta of 3.01 underscores volatility, with recent pullbacks after sharp rallies, but strong cash position ($1.5B pro forma) and $20B+ peak revenue potential fuel optimism; analyst targets average $601.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from over 351 total bots that trade thousands of tickers across diverse strategies like swing trading, trend following, hedging, and volatility exploitation in sectors including biotech via BIB ETF. These 25 featured bots excel in current market conditions, posting annualized returns up to +208%, win rates as high as 94.92% for biotechnology-focused agents, profit factors reaching 25.83, and profit-to-drawdown ratios over 22. Timeframes vary from 5-minute scalps to 62-day holds, with no balance minimums for signal agents and customizable risk management for virtual and brokerage types. Designed to outperform benchmarks, they highlight high-growth areas like semiconductors, energy, and healthcare. Explore Tickeron’s AI tools for data-driven trading signals tailored to today's volatility.
Head-to-Head Comparison
ABBV's established business model emphasizes diversified commercial revenues ($392B market cap) and immunology/oncology drivers, contrasting IONS ($12B cap) and PRAX ($8B cap)'s pipeline-centric biotech approaches in RNA therapies and CNS precision meds. Growth drivers diverge: ABBV relies on Skyrizi/Rinvoq uptake post-Humira, IONS on rare disease launches like olezarsen, and PRAX on NDA catalysts for tremor/epilepsy. Recent momentum favors PRAX's 689% 1-year surge over IONS's 116% and ABBV's 8%, though high PRAX beta (3.01) amplifies risks versus ABBV's stability (beta 0.33). Valuation sensitivity shows ABBV's PE at 93x with dividends versus unprofitable peers; sector exposure spans broad pharma for ABBV, rare diseases for IONS, and CNS for PRAX. Market sentiment tilts bullish across all, balancing trade-offs in stability versus upside potential.
Tickeron AI Verdict
Tickeron’s AI leans toward PRAX in the current environment, given its superior trend consistency from Phase 3 wins and NDA momentum, alongside relative positioning with 689% 1-year gains and analyst upside to $601. While ABBV offers stability and IONS solid catalysts, PRAX's growth trajectory and biotech sector tailwinds present higher probabilistic outperformance potential amid volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s), and PRAX’s FA Score reflects 0 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- IONS’s FA Score: 0 green, 5 red.
- PRAX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s), and PRAX’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 5 bearish.
- IONS’s TA Score: 4 bullish, 5 bearish.
- PRAX’s TA Score: 4 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а -0.43% price change this week, while IONS (@Biotechnology) price change was +0.51% , and PRAX (@Biotechnology) price fluctuated +1.86% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
IONS is expected to report earnings on May 06, 2026.
PRAX is expected to report earnings on May 13, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | IONS | PRAX | |
| Capitalization | 368B | 12.4B | 8.81B |
| EBITDA | 17.6B | -273.12M | -326.06M |
| Gain YTD | -8.262 | -4.980 | 7.261 |
| P/E Ratio | 87.74 | N/A | N/A |
| Revenue | 61.2B | 944M | 0 |
| Total Cash | 5.26B | 2.68B | 599M |
| Total Debt | 67.5B | 2.07B | 110K |
ABBV | IONS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 14 | 60 | |
SMR RATING 1..100 | 1 | 98 | |
PRICE GROWTH RATING 1..100 | 58 | 41 | |
P/E GROWTH RATING 1..100 | 40 | 73 | |
SEASONALITY SCORE 1..100 | 2 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (100) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than IONS’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (60) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than IONS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as ABBV (58) in the Pharmaceuticals Major industry. This means that IONS’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's P/E Growth Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (73) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than IONS’s over the last 12 months.
| ABBV | IONS | PRAX | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 37% | 2 days ago 69% | N/A |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 69% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 47% | 2 days ago 69% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 58% | 2 days ago 73% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 47% | 2 days ago 71% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 51% | 2 days ago 67% | 2 days ago 88% |
| Advances ODDS (%) | 3 days ago 57% | 3 days ago 67% | 18 days ago 85% |
| Declines ODDS (%) | 5 days ago 47% | 5 days ago 65% | 5 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 71% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 45% | 2 days ago 62% | 2 days ago 87% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -2.10% | ||
| BMY - ABBV | 58% Loosely correlated | -1.43% | ||
| PFE - ABBV | 57% Loosely correlated | -1.10% | ||
| BIIB - ABBV | 55% Loosely correlated | -2.34% | ||
| AMGN - ABBV | 54% Loosely correlated | -1.29% | ||
| NVS - ABBV | 53% Loosely correlated | -0.65% | ||
More | ||||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | -1.28% | ||
| BEAM - PRAX | 40% Loosely correlated | +4.18% | ||
| BHVN - PRAX | 37% Loosely correlated | -2.34% | ||
| RAPP - PRAX | 35% Loosely correlated | -0.15% | ||
| VERU - PRAX | 35% Loosely correlated | -2.06% | ||
| RXRX - PRAX | 35% Loosely correlated | -0.91% | ||
More | ||||